COMP <GO>
BIO vs ALMR // EV/EBITDA & P/E VALUATION
Bio-Rad Laboratories Inc. (NYSE) VS. Alamar Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: BIO 2
— ALMR 0
■ METRIC PARITY
LAST: $384.40 (-0.19%) • MKT CAP: $10.28B
valuation
60.4x
LAST: $34.04 (-0.76%) • MKT CAP: $2.36B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. ALMR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | ALMR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 60.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 1.80% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 29.40% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 50.8 | +8.19 | BIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $2.36B | $7.92B | BIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | ALMR REV | BIO GROSS % | ALMR GROSS % | BIO FCF | ALMR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $0 | 51.9% | — | $374.6M | — |
| FY 2024 | $2.57B | — | 53.7% | — | $289.6M | — |
| FY 2023 | $2.67B | — | — | — | $254.7M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
ALMR // BETA —